Form 4: Keros Therapeutics Director Receives Significant Equity Compensation Package

Keros Therapeutics, Inc. Director Mary Ann Gray was granted 5,250 restricted stock units and 10,500 stock options on June 4, 2025, as part of her compensation.

Summary

• Mary Ann Gray, a Director of Keros Therapeutics, Inc. (KROS), acquired 5,250 shares of common stock through a restricted stock unit (RSU) award on June 4, 2025.
• She also received a grant of 10,500 stock options with an exercise price of $14.82 per share on the same date.
• The RSUs are scheduled to fully vest on the earlier of June 4, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent upon her continued service.
• The stock options will vest in equal quarterly installments over the 12 months following the grant date, with full vesting by the 2026 annual meeting, also subject to her continued service.
• The granted stock options have an expiration date of June 3, 2035.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation filing, indicating continued alignment of director interests with shareholders. It does not contain any negative operational or financial news.

Positives

• The granting of equity compensation to a director aligns their financial interests with those of shareholders, incentivizing long-term company performance.
• The vesting conditions tied to continued service promote the retention of key personnel within the company.

Risks

• The ultimate value realized from the RSU award and stock options is directly dependent on the future stock price performance of Keros Therapeutics, Inc.
• Unvested awards would be forfeited if the director's service to the company ceases before the specified vesting dates.

Future Outlook

This filing primarily details past compensation grants and their future vesting schedules, rather than providing a forward-looking statement on company performance or strategic guidance. The future value of these awards depends on the company's stock performance.

Industry Context

Equity compensation, including restricted stock units and stock options, is a common practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize directors and executives. This aligns their financial interests with the long-term success of the company and its shareholders.

Comparison to Industry Standards

• The compensation structure involving RSUs and stock options with vesting conditions tied to continued service is a standard practice for director compensation in publicly traded companies, particularly within the biotech sector.
• Specific comparable companies, projects, or results are not detailed in this filing, as it focuses solely on an individual's compensation.

Stakeholder Impact

• Shareholders: The granting of equity compensation aligns the director's interests with shareholders, potentially leading to better long-term decision-making and value creation.

Next Steps

• Monitoring the vesting of the RSUs and stock options on June 4, 2026, or the 2026 annual meeting, subject to continued service.
• Potential exercise of stock options by Mary Ann Gray before June 3, 2035, subject to vesting and market conditions.

Key Dates

Keywords

Keros Therapeutics, KROS, Form 4, SEC Filing, Insider Transaction, Equity Compensation, Restricted Stock Units, RSU, Stock Options, Director Compensation, Beneficial Ownership